NEW YORK – Molecular diagnostic reagent developer BioGX and Bosch Healthcare Solutions, a subsidiary of the Bosch Group, announced Wednesday a partnership to develop point-of-care infectious disease tests for Bosch's Vivalytic platform.
Birmingham, Alabama-based BioGX will develop, manufacture, and supply reagents for the Vivalytic cartridges, along with providing custom reagent manufacturing services for Vivalytic open system users. The companies said they will work together to seek regulatory approvals in different countries for in vitro diagnostic use.
Bosch's Vivalytic system uses cartridges preloaded with the necessary reagents, which allows for full automation and a faster turnaround time, according to the Waiblingen, Germany-based company. It can perform multiple kinds of tests, including endpoint PCR, quantitative real-time PCR, melt curve analysis, and microarray detection. The system is commercially available in the European Union.
Last month, Bosch said it was working with Randox Laboratories of Northern Ireland to develop a coronavirus test for the Vivalytic system.